AtriCure Earnings Call Highlights Profitable Growth Pivot

Atricure, Inc. ((ATRC)) has held its Q1 earnings call. Read on for the main highlights of the call.

AtriCure’s latest earnings call projected a confident tone, underscoring durable double‑digit revenue growth, strong margin expansion, and a decisive turn toward profitability. Management acknowledged pockets of weakness in minimally invasive ablation and select international markets, but framed them as manageable headwinds amid robust U.S. adoption and rapid clinical trial momentum.

Top-Line Growth Remains Solidly in Double Digits

AtriCure reported Q1 2026 worldwide revenue of $141.2 million, up 14.3% on a reported basis and 12.8% in constant currency versus Q1 2025. Sequentially, sales ticked up about 1% versus Q4 2025, signaling steady demand even after a strong prior quarter.

U.S. Performance Anchors Overall Momentum

U.S. revenue climbed to $116.2 million, an increase of 14.9% year over year and the main engine of the company’s growth. Management highlighted broad strength across pain management, open ablation, and appendage management, driven by rapid adoption of newer products.

Profitability Inflects with EBITDA and EPS Improvement

Adjusted EBITDA nearly doubled to $17.1 million from $8.8 million in the prior‑year quarter, marking a 95% jump. Net income turned roughly breakeven at about $0.1 million, with EPS at $0.00 compared with a loss of $0.14 per share a year ago.

Gross Margin Expansion Highlights Operating Leverage

Gross margin expanded to 77.4%, up 246 basis points from Q1 2025, reflecting a richer product mix and strong U.S. contributions. Management cautioned that this exceptionally strong level will normalize somewhat as manufacturing investments ramp later in the year.

Pain Management Franchise Accelerates on cryoSPHERE MAX

Pain management revenue surged 28% year over year, making it one of the fastest‑growing pieces of the portfolio. The cryoSPHERE MAX probe led the way, accounting for roughly 70% of pain segment sales and achieving about 70% adoption within existing pain accounts.

Appendage Management Benefits from AtriClip FLEX-Mini

Appendage management revenue grew 16% worldwide, underlining a healthy structural growth driver for the company. In the U.S., open appendage sales reached $48.4 million, up 14.9% year over year, with AtriClip FLEX‑Mini now contributing about 40% of that line and continuing to gain market share.

Open Ablation Strength Driven by EnCompass Clamp

Worldwide open ablation revenue advanced 15% year over year, reinforcing AtriCure’s core cardiac surgery franchise. In the U.S., open ablation sales increased 17.3% to $39.1 million, powered by strong EnCompass clamp adoption domestically and growing usage in Europe.

BoxX-NoAF Trial Enrollment Far Ahead of Plan

The company has enrolled about 300 of the planned 960 patients in the BoxX‑NoAF study since Q4 2025, significantly ahead of its original cadence. Management now expects to finish enrollment around year‑end, nearly a year early, positioning the trial as a potential landmark source of clinical evidence.

Balance Sheet Strength Supports Growth Investments

AtriCure ended Q1 with approximately $146 million in cash and investments, providing ample flexibility for R&D and commercial expansion. Cash burn improved versus last year, and management expects positive cash flow for the remainder of 2026 with full‑year cash generation moderately above 2025 levels.

Guidance Reaffirmed Amid Manufacturing and R&D Spend

The company reiterated 2026 guidance for revenue of $600–$610 million, implying about 12–14% growth, adjusted EBITDA of $80–$82 million, and adjusted EPS of roughly $0.09–$0.15. It also forecast mid‑single‑digit sequential growth in Q2 and modest full‑year gross‑margin improvement despite higher manufacturing and BoxX‑NoAF trial costs.

MIS Ablation Faces Ongoing Headwinds

Minimally invasive ablation remains a weak spot, with U.S. sales down about 25% year over year to $6.4 million in the quarter. Management pointed to continued headwinds and slower volumes for hybrid therapy, as physicians weigh evolving ablation technologies.

International Growth Tempered by U.K. and Asia Volatility

International revenue reached $25.0 million, rising 11.5% on a reported basis but only 3.3% in constant currency, reflecting softer underlying demand. Uncertainty in the U.K. and lumpy ordering patterns from Asia‑Pacific distributors weighed on growth, though management framed the issues as episodic rather than structural.

Operating Expenses Rise with R&D and SG&A Investments

Total operating expenses increased by $10.2 million, or 10.3%, to $108.8 million compared with Q1 2025. R&D spending grew 7.6% on accelerated BoxX‑NoAF enrollment, while SG&A rose 11.2% to support the expanding sales footprint and product launches.

Manufacturing Expansion to Temper Margin Upside

While Q1 showcased best‑in‑class gross margins, management expects only modest full‑year improvement over 2025 as new manufacturing facilities come online in the second half. These expansions will add cost in the near term but are designed to support higher volumes and more resilient supply over time.

Competitive and PFA Market Dynamics Create Noise

Competition in appendage management is intensifying, with major device players active and planning entries, while pulsed field ablation continues to reshape the electrophysiology landscape. Hybrid and convergent procedures are seeing referral delays as clinicians experiment with multiple PFA catheters, adding near‑term uncertainty to certain growth vectors.

BoxX-NoAF Acceleration Pulls Forward Near-Term Spend

The faster‑than‑planned pace of BoxX‑NoAF enrollment is a strategic win but raises near‑term R&D costs over the next three quarters. Management framed this as an intentional investment to secure earlier and stronger clinical evidence that can support long‑term market adoption.

In summary, AtriCure delivered a quarter marked by strong U.S. growth, sharp profitability improvement, and outsized margin performance while continuing to invest aggressively in clinical and manufacturing infrastructure. Although MIS ablation and select international markets remain soft, management’s reaffirmed guidance and early BoxX‑NoAF progress suggest confidence in sustaining double‑digit growth and expanding earnings power.